US FDA Accepts New Drug Application of Astellas for Fezolinetant
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of Astellas Pharma Inc. for fezolinetant, an investigational oral, nonhormonal compound that is seeking approval for the treatment of moderate to serious vasomotor symptoms (VMS) that are associated with menopause. VMS, which is characterized by hot flashes and night sweats, is […]
Continue Reading